Antech Molecular Innovations

Antech Molecular Innovations is a veterinary molecular diagnostics company structured as a joint venture between Antech Diagnostics and Sentinel Biomedical. The business focuses on developing and commercializing molecular tests for earlier, less invasive detection of disease in companion animals, particularly cancer in dogs. Its best-known commercial products are the CADET BRAF and CADET BRAF PLUS urine-based assays for detection of canine transitional cell carcinoma and urothelial carcinoma, including cancers affecting the bladder, urethra, and prostate. The company operates within the broader Antech and Mars veterinary diagnostics ecosystem and appears oriented toward veterinary diagnostic R&D and commercialization rather than human therapeutics. Overall, it is best characterized as a specialized pet-health molecular diagnostics venture with commercial-stage oncology testing.